Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Condition: Breast Cancer; Ovarian Cancer; Gynecological Cancer; Head and Neck Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Non-squamous Cell Lung Cancer
MeSH terms: Lung Neoplasms; Small Cell Lung Carcinoma
Intervention: PM01183 + paclitaxel +/- bevacizumab
Intervention description: PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion
paclitaxel: 6 mg/ml concentrate for solution for infusion
bevacizumab: 25 mg/ml concentrate for solution for infusion
Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients
Intervention MeSH terms: Paclitaxel; Bevacizumab
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 69.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: No

Summary:

      Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in
      patients with solid tumors
    

Eligibility criteria:

        Inclusion Criteria:

          -  Voluntarily signed and dated written informed consent

          -  Age between 18 and 75 years old (both inclusive)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1

          -  Life expectancy ≥ 3 months.

          -  Patients with a histologically/cytologically confirmed diagnosis of advanced and/or
             unresectable disease of any of the following tumors:

               1. Breast cancer

               2. Epithelial ovarian cancer or gynecological cancer

               3. Head and neck squamous cell carcinoma

               4. Non-small cell lung cancer

               5. Small cell lung cancer

               6. Platinum-refractory germ-cell tumors.

               7. Adenocarcinoma or carcinoma of unknown primary site

          -  Adequate bone marrow, renal, hepatic, and metabolic function

          -  Recovery to grade ≤ 1 or to baseline from any Adverse Event (AE) derived from previous
             treatment (excluding alopecia of any grade).

          -  Pre-menopausal women must have a negative pregnancy test before study entry and agree
             to use a medically acceptable method of contraception throughout the treatment period
             and for at least six weeks after treatment discontinuation

        Exclusion Criteria:

          -  Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel

          -  Patients who have previously discontinued paclitaxel-based regimes due to drug related
             toxicity.

          -  Known hypersensitivity to bevacizumab or any component of its formulation

          -  Patients who have previously discontinued bevacizumab-containing regimes due to
             drug-related toxicity.

          -  More than three prior lines of chemotherapy

          -  Less than three months since last taxane-containing therapy.

          -  Wash-out period:

               1. Less than three weeks since the last chemotherapy-containing regimen

               2. Less than three weeks since the last radiotherapy dose

               3. Less than four weeks since last monoclonal antibody-containing therapy

          -  Concomitant diseases/conditions:

        Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic
        attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary
        embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or
        oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral
        neuropathy, Symptomatic or progressive brain metastases or leptomeningeal disease.

          -  Men or pre-menopausal women who are not using an effective method of contraception as
             previously described; actively breast feeding women.

          -  Patients who have pelvic irradiation with doses ≥ 45 Grays (Gy).

          -  History of previous bone marrow and/or stem cell transplantation.

          -  Confirmed bone marrow involvement